Understanding side effects in melanoma patients treated with immune therapy
Official title: Immune-Related Adverse Events in Melanoma Patients Receiving Adjuvant Immune Checkpoint Inhibitor Therapy
Funded at University of Tx Md Anderson Can Ctr · NIH-10893992 · Data updated 2026-11-12
This study is looking at the side effects that melanoma patients might experience while getting treatment with immune checkpoint inhibitors, to better understand how these treatments can help them live longer but may also cause some uncomfortable issues, and it’s for anyone who wants to know more about the long-term effects of this therapy on their health and quality of life.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | August 18, 2021 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $113,868 |
| NIH project number | 5K01AI163412-04 |
| Project ID | NIH-10893992 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are melanoma patients who are starting adjuvant immune checkpoint inhibitor therapy.
✕Less likely to help
Patients who are not receiving immune checkpoint inhibitors or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates the side effects experienced by melanoma patients receiving immune checkpoint inhibitors (ICIs) as part of their treatment. It aims to understand how these therapies, while improving survival rates, can also lead to inflammatory responses and autoimmune issues that affect patients' quality of life. By following a group of 240 melanoma patients over two years, the study will assess the incidence and severity of these immune-related adverse events (irAEs) and explore their correlation with inflammation markers in the body. The goal is to provide a clearer picture of the long-term effects of ICI therapy on patients' health and well-being.
Why it matters
Potential benefit: If successful, this research could lead to improved management of side effects for melanoma patients undergoing immune therapy, enhancing their overall quality of life.
How similar studies have gone: Previous research has shown that understanding the side effects of immune therapies can lead to better patient care, indicating that this approach has potential for success.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Hassan, Noha Abdelwahab Hassan Ali — University of Tx Md Anderson Can Ctr
- Study coordinator: Hassan, Noha Abdelwahab Hassan Ali
Related research
Other NIH-funded projects on the same topics.
-
Characterizing the psychological symptoms in melanoma patients on immunotherapy
A long-term study follows adults with advanced skin cancer who are starting immune checkpoint therapy to understand the pattern of emotional and psychological symptoms they experience.
-
Easing psychological symptoms in women with breast cancer through moderate aerobic exercise
This project finds out if a regular program of moderate aerobic exercise can reduce anxiety and related psychological symptoms in women undergoing breast cancer treatment while exploring personal, neighborhood, and blood-based (epigenetic) factors that might explain who benefits most.
-
Melanoma vaccine built from tiny spherical nucleic acids
A new kind of cancer vaccine using tiny spherical nucleic acids to help the immune system fight advanced melanoma.
-
Injecting immune-boosting medicine into melanoma tumors to help the immune system reject them
This gives an immune-boosting drug directly into melanoma tumors in pet dogs to help their T cells find and destroy the cancer.
-
SIRT6 and melanoma growth and spread
Researchers are seeing if blocking a protein called SIRT6 can help stop melanoma from growing and spreading in people with melanoma.
-
How tumor cell stress and nearby support cells help melanoma spread
This project looks at whether blocking a tumor cell stress response and changing how nearby support cells behave might keep melanoma cells from surviving, spreading, and resisting treatment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.